Drugs / huCART19
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06056102 | May 2024 → Dec 2028 expected | end stage renal failure, kidney failure | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT03620058 | Sep 2018 → Jan 2036 expected | acute lymphoblastic leukemia | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03549442 | May 2018 → Mar 2036 expected | plasma cell myeloma | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02374333 | Mar 2014 → Sep 2021 | acute lymphoblastic leukemia, diffuse large B-cell lymphoma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05674175 | Jan 2023 → Jul 2028 expected | B-cell acute lymphoblastic leukemia, lymphoblastic lymphoma | Stephan Grupp MD PhD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05480449 | Sep 2022 → Sep 2027 expected | B-cell acute lymphoblastic leukemia, lymphoblastic lymphoma | Stephan Grupp MD PhD | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03792633 | Jan 2019 → Apr 2024 | B-cell acute lymphoblastic leukemia | University of Pennsylvania | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-08-19 | Eutilex | Results 경쟁자 털어낸 유틸렉스…EU307 성공이끌 핵심열쇠 두 가지 eutilex.com ↗
혈액암 CAR-T 치료제 ‘킴리아’를 개발해 노바티스로 기술이전한 미국 펜실베이니아대 의대의 칼 준 교수팀은 IL-18 사이토카인을 탑재한 huCART19-IL18을 통해 기존 CAR-T 대비 보다 우수한 치료효능을 확인한 임상 결과를 공개했다. |
| 2017-05-30 | Novartis Pharmaceuticals | Results Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients novartis.com ↗
Results from the pilot study also showed that eight of nine patients had no signs of CLL in their bone marrow at three months as tested by flow cytometry and/or analysis for minimal residual disease (MRD)[1]. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-19 | Eutilex | 경쟁자 털어낸 유틸렉스…EU307 성공이끌 핵심열쇠 두 가지 eutilex.com ↗ |
| 2017-05-30 | Novartis Pharmaceuticals | Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients novartis.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huCART19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480449 ↗ |
| Known as | CTL119 | “with or without huCART19 (also known as CTL119)” NCT03549442 ↗ |
| Known as | humanized CART19 cells | “The investigational agent in this protocol is humanized CART19 cells (huCART19).” NCT05480449 ↗ |
| Action | Deplete | “CAR T cells targeting Bmems and LLPCs eliminates donor-specific allo-antibodies” PMID 38118406 ↗ Dec 2023 |
| Modality | Cell therapy | “humanized CD19 CAR T-cell product (huCART19)” PMID 34156874 ↗ Jun 2021 |
| Route | Intravenous | “CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection” NCT02374333 ↗ |
| Target | CD19 | “CD19-targeted chimeric antigen receptor (CAR)-modified T cells” PMID 34156874 ↗ Jun 2021 |